For the committee, some of the reasons it used to reject adding Pompe disease to Australia’s newborn bloodspot screening programs are perversely the same as those it invoked to support the addition of Hurler (MPS I) and Hunter (MPS II) syndromes.
Decision-making at its nadir, exposing the cruelty of incoherence
September 16, 2025 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Prescription medicines at the centre of Trump’s 'Great Healthcare Plan'
January 18, 2026 - - Latest News -
Boehringer Ingelheim again recognised as a top employer across Australia and New Zealand
January 18, 2026 - - Latest News -
The quiet and steady privatisation of this critical public health program
January 18, 2026 - - Latest News -
AbbVie to consolidate Sydney operations with move to CBD headquarters
January 15, 2026 - - Latest News -
Anne Harris steps down after defining leadership during COVID and lasting impact on Medicines Australia
January 14, 2026 - - Latest News -
AusBiotech joins Trade Diversification Network to boost global life sciences partnerships
January 13, 2026 - - Australian Biotech -
Reread this document - even its redactions reveal that change might be coming
January 13, 2026 - - Latest News

